Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Bevacizumab in Glioblastoma Multiforme: NCT06496971 Clinical Landscape Report 2026
15 October 2026
NCT06496971 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bulumtatug fuvedotin in Metastatic Triple-Negative Breast Carcinoma: NCT06492005 Clinical Landscape Report 2026
15 October 2026
NCT06492005 clinical landscape for Metastatic Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
CTX-131 in Acute Myeloid Leukemia: NCT06492304 Clinical Landscape Report 2026
15 October 2026
NCT06492304 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bicalutamide in High grade glioma: NCT06501911 Clinical Landscape Report 2026
15 October 2026
NCT06501911 clinical landscape for High grade glioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Large B-cell lymphoma: NCT06500273 Clinical Landscape Report 2026
15 October 2026
NCT06500273 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab/Hyaluronidase in Relapsing classical Hodgkin lymphoma: NCT06504394 Clinical Landscape Report 2026
15 October 2026
NCT06504394 clinical landscape for Relapsing classical Hodgkin lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Temozolomide in Glioblastoma: NCT06504381 Clinical Landscape Report 2026
15 October 2026
NCT06504381 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
UTAA09/17 in Large B-cell lymphoma: NCT06503211 Clinical Landscape Report 2026
15 October 2026
NCT06503211 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Diffuse Large B-Cell Lymphoma: NCT06503263 Clinical Landscape Report 2026
15 October 2026
NCT06503263 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
PLL-001 in Amyotrophic Lateral Sclerosis: NCT06513546 Clinical Landscape Report 2026
15 October 2026
NCT06513546 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Datopotamab Deruxtecan in Recurrent Triple-Negative Breast Carcinoma: NCT06508216 Clinical Landscape Report 2026
15 October 2026
NCT06508216 clinical landscape for Recurrent Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Lenalidomide in Diffuse large B-cell lymphoma recurrent: NCT06508658 Clinical Landscape Report 2026
15 October 2026
NCT06508658 clinical landscape for Diffuse large B-cell lymphoma recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development whi…